Decitabine may open the chromatin structure of leukemia cells making them accessible to the calicheamicin epitope of gemtuzumab ozogamicin (GO). A total of 110 patients (median age 70 years; range 27-89 years) were treated with decitabine and GO in a trial designed on model-based futility to accommodate subject heterogeneity: group 1: relapsed/refractory acute myeloid leukemia (AML) with complete remission duration (CRD) o1 year (N = 28, 25%); group 2: relapsed/refractory AML with CRD ⩾ 1 year (N = 5, 5%); group 3: untreated AML unfit for intensive chemotherapy or untreated myelodysplastic syndrome (MDS) or untreated myelofibrosis (MF; N = 57, 52%); and group 4: AML evolving from MDS or relapsed/refractory MDS or MF (N = 20, 18%). Treatment consisted of decitabine 20 mg/m 2 daily for 5 days and GO 3 mg/m 2 on day 5. Post-induction therapy included five cycles of decitabine+GO followed by decitabine alone. Complete remission (CR)/CR with incomplete count recovery was achieved in 39 (35%) patients; group 1 = 5/28 (17%), group 2 = 3/5 (60%), group 3 = 24/57 (42%) and group 4 = 7/20 (35%). The 8-week mortality in groups 3 and 4 was 16% and 10%, respectively. Common drug-related adverse events included nausea, mucositis and hemorrhage. Decitabine and GO improved the response rate but not overall survival compared with historical outcomes in untreated AML ⩾ 60 years.
INTRODUCTION
Elderly patients (⩾60-65 years) with acute myeloid leukemia (AML) have a poor prognosis attributable to having disease inherently more resistant to current standard cytotoxic agents and/or relatively poor tolerance of these agents. [1] [2] [3] Elderly patients with AML also more frequently have an antecedent hematological disorder, unfavorable cytogenetics and poorer performance status at presentation. 2, 4 Among younger patients (o 65 years of age), traditional induction chemotherapy (for example, anthracycline and cytarabine) produces complete remission (CR) in~50-75% of patients. 5 Unfortunately, a significant number of younger patients with AML (especially those with adverse cytogenetic features, adverse molecular mutations or antecedent hematological disorder) will be refractory to induction therapy or relapse after initial response to induction therapy. The outcomes of these patients are dismal, with low response rates and poor long-term survival with salvage therapy. [6] [7] [8] The development of novel agents and/or combinations for these patient groups is warranted.
Antibody drug conjugate strategies envisage one such novel approach. CD33 is expressed by myeloid blast cells in 480% of patients with AML suggesting that antibodies to CD33 may have specific therapeutic benefit in the treatment of AML. 9, 10 Gemtuzumab ozogamycin (GO; Mylotarg, Pfizer Inc., New York, NY, USA) is a humanized anti-CD33 monoclonal antibody covalently linked to a semisynthetic derivative of a potent toxin, calicheamicin. 11, 12 GO has been used in combination with induction therapy in AML with improved outcomes 11, [13] [14] [15] [16] [17] particularly among elderly patients and those with intermediate-or good-risk cytogenetics. Decitabine (Dacogen, Eisai Inc., New Jersey, NJ, USA; 5-aza-2′-deoxycytidine) exerts its antineoplastic activity by direct incorporation into DNA with subsequent inhibition of DNA methyltransferase. 18 DNA hypomethylation from DNA methyltransferase inhibition results in re-expression of tumor suppressor genes. 19, 20 In a phase III study in elderly patients (⩾60 years) with previously untreated AML, decitabine resulted in a response rate (CR/complete remission with incomplete recovery of platelets) of 18%. 21 In primary AML samples, response to GO depends on Syk expression. 22 GO binds to CD33 resulting in the phosphorylation of Syk, a protein kinase that docks to the intra-cytoplasmic tail of CD33. Syk then complexes with SHP-1, a protein phosphatase. 22 Activated Syk in this context acts as a tumor suppressor in hematopoietic and solid tumors. DNA hypermethylation can silence Syk expression thereby abrogating the antiproliferative effect of GO on AML cells. 23, 24 Hypomethylating agents may restore Syk expression, consequently re-establishing sensitivity of AML cells to GO. Prior exposure of AML cells to hypomethylating agent such as decitabine sensitize them to GO by reducing the expression of multidrug resistance protein-1 or by enhancing DNA intercalation by calicheamicin. 25 Nand et al. 26 evaluated a combination of 5-azacitidine and GO in 133 elderly patients with newly diagnosed myelodysplastic syndrome (MDS) and AML. They divided patients into good-risk (N = 79) and poor-risk (N = 54) groups. The good-risk group included patients who were 60-69 years or had a performance status of 0 or 1; the poor-risk group included patients who were ⩾ 70 years or had a performance status of 2 or 3. Responses (CR/CR with incomplete count recovery (CRi)) were seen in 44 and 35% of the good-risk and poor-risk patients, respectively. Median overall survival (OS) was 11 months in both risk groups. Early mortality was noted in 8% of the goodrisk and 13% of the poor-risk patients. Although these studies were ongoing, we evaluated the combination of decitabine and GO in newly diagnosed and relapsed AML and high-risk MDS patients treated at our center. Herein, the results are presented.
PATIENTS AND METHODS

Patient eligibility
Eligibility criteria included patients ⩾ 18 years of age with a diagnosis of AML (other than acute promyelocytic leukemia) with refractory/relapsed disease and/or patients with newly diagnosed AML not a candidate for intensive chemotherapy in the opinion of the treating physician; previously treated, relapsed, refractory or newly diagnosed, high-risk MDS (intermediate-2 or high by the International Prognostic Scoring System or ⩾ 10% blasts); 27 and previously treated, relapsed, refractory or newly diagnosed, with intermediate-or high-risk myelofibrosis (MF) (that is, score ⩾ 1 by the Lille scoring system) 28 or MF with symptomatic splenomegaly. Other inclusion criteria were: Eastern Cooperative Oncology Group performance status (PS) ⩽ 3; serum creatinine ⩽ 2.0 mg/dl; serum bilirubin ⩽ 2.0 mg/dl; serum transaminase ⩽ 2.5 times the upper limit of the normal range or ⩽ 5 times the upper limit of the normal range if the transaminase elevation was deemed related to the underlying disease. This was a single-center, open-label, nonrandomized study. All patients signed an informed consent form approved by the University of Texas/MD Anderson Cancer Center Institutional Review Board. The study was conducted in accordance with the Declaration of Helsinki. ClinicalTrials.gov identifier: NCT00882102.
Treatment regimen
The induction regimen included 5 days of decitabine at 20 mg/m 2 given intravenously (i.v.) over 60-90 min. The day-5 decitabine dose was followed by GO at 3 mg/m 2 given i.v. for one dose. Patients underwent a bone marrow aspiration on day 14 ± 3 days. Patient's whose day-14 bone marrow showed ⩾ 20% cellularity with ⩾ 5% blasts received an additional course of decitabine 20 mg/m 2 i.v. daily for 5 days starting on day 15. Patients with response or with no obvious progression could receive postinduction therapy with up to five additional cycles of decitabine and GO as during induction, without the day-15 decitabine. Post-induction cycles were repeated every 4-8 weeks, depending on the recovery of neutrophil and platelet counts and toxicity. Patients who maintained clinically relevant response (CR or CRi) at the end of post-induction therapy could receive maintenance therapy with decitabine alone every 4-8 weeks for a total of up to 24 cycles of therapy.
Response criteria and definitions
Responses were according to established criteria. 29 CR was defined by the presence of 5% blasts or less in the bone marrow, with 41.0 × 10 9 /l neutrophils and 4100 × 10 9 /l platelets in the peripheral blood. CRi was as for CR, but for residual neutropenia (o1.0 × 10 9 /l) or thrombocytopenia (o100 × 10 9 /l). 30 
Statistical design
The primary objective of this single-arm phase II study was to assess whether the combination of decitabine and GO could increase the CR rate by 10-15% as compared with the historical response rates in similar patients treated at our center. Secondary objectives were to assess the OS and CRD. Considering the heterogeneity in historical outcomes among patients based on the underlying disease, duration of prior remission and on whether they had new or relapsed disease, patients were up-front classified into four groups: group 1: relapsed/refractory AML with CRD o 1 year; group 2: relapsed/refractory AML with CRD ⩾ 1 year; group 3: untreated AML unfit for intensive chemotherapy or untreated MDS or untreated MF; and group 4: AML evolving from MDS or relapsed/refractory MDS or MF. To account for the heterogeneity of expected remission rates in each group, a model-based Bayesian design 31 with interim stopping rules for futility was implemented. The flexibility of design allows for specific decisions to be made for each group such that enrollment in some groups may be stopped early owing to futility while other groups with better remission rates continue to enroll patients. Specifically, for our study, if, within a given group, it was unlikely that decitabine in combination with GO would increase the CR rate by 10-15% when compared with historical treatment, accrual to that group was to be terminated. The priors for group effects were calibrated to reflect a historical response rate of 15%, 50%, 44% and 28%, respectively, in groups 1 through 4.
Data analysis
Unadjusted probabilities of OS and CRD were estimated using the method of Kaplan and Meier. 32 A Bayesian logistic regression model was fit to assess the decitabine combined with GO treatment effect on CR rate within each group of patients, which included group indicators, treatment indicator within each group, as well as relevant clinical characteristics, such as age, white blood count, platelet count, bone marrow blast percentage, karyotype and Eastern Cooperative Oncology Group PS. The priors for the group-specific decitabine combined with GO treatment effect were calibrated to reflect a similar response rate as historical controls within each group, but with much larger variability (that is, noninformative priors for the experimental treatment effect). Similarly for OS, a Bayesian Weibull regression model was fit for each endpoint, with noninformative priors for all the model parameters as well as the scale parameter for Weibull distribution. All statistical analyses were carried out in Splus 8.2 and WinBugs1.4.
RESULTS
Study group
A total of 110 patients were treated. Their characteristics are shown in Table 1 . The median age for all patients was 70 years (range, 27-89 years). Eighty-four patients had AML including 16 patients with preexisting MDS and 4 patients with preexisting myelofibrosis, 22 patients had high-risk MDS including chronic myelomonocytic leukemia in 6 patients and MDS/myeloproliferative neoplasm unclassified in 1 patient, and 4 patients had MF. Forty-four patients (40%) had high-risk cytogenetics and 11 of 95 tested patients (12%) were FLT3 mutated (including ITD and D835). Patients were enrolled into the four predefined groups as follows: group 1 = 28 patients (25%; age, 62 years (range, 26-83)); group Response and outcomes by predefined groups Responses and outcomes by predefined groups are discussed below and are shown in Table 2 and Figure 1 . Abbreviations: AML; acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete count recovery; MDS; myelodysplastic syndrome; MF; myelofibrosis; OS, overall survival; R/R, relapsed or refractory.
Time (months)
Overall survival probability Phase II study of decitabine and gemtuzumab in AML N Daver et al enrolled in this group including 40 patients with AML and 17 patients with untreated MDS or MF (including 10 MDS, 4 chronic myelomonocytic leukemia, 1 MDS/myeloproliferative neoplasm unclassified and 2 MF). CR/CRi was achieved in 18 of the 40 elderly/unfit newly diagnosed AML patients (45%) with a median OS of 7.0 months and 8-week mortality of 15%. On comparison to a matched cohort of 76 newly diagnosed AML patients who were not candidates for intensive chemotherapy and treated with hypomethylator therapy-based protocols (including single-agent decitabine protocols, decitabine with or without valproate, 5-azacytidine with or without vorinostat) at our institution between 2001 and 2010, the CR/CRi rate, median CRD, median OS and 8-week mortality were 30% (P = 0.114), 8.1 months (P = 0.15) and 16% (P = 0.91), respectively. Although decitabine and GO trended toward a superior response rate compared with historical data, this did not result in improved survival in this group (Supplementary Table 1 ). The median number of cycles administered was 3 (range, 1-23). In patients who achieved CR/CRi the median number of cycles administered was 7 (range, 1-23) and the median number of cycles to response was 2 (range, 1-5).
Among the 15 untreated high-risk MDS patients the CR/CRi rate, median OS and 8-week mortality were 33%, 5.7 months and 20%, respectively. On comparison to a matched cohort of 103 high-risk MDS patients treated at our institution with hypomethylator therapy-based protocols (including single-agent decitabine, decitabine with or without valproate, 5-azacytidine with or without vorinostat) between 2001 and 2010, the CR/CRi rate, median OS and 8-week mortality were 59% (P = 0.06), 19.9 months (P = 0.03) and 7% (P = 0.09), respectively. Thus, the response rate, OS and 8-week mortality were inferior among the patients who received decitabine in combination with GO (Supplementary Table 1 ).
Group 4: AML evolving from MDS, or relapsed/refractory MDS or MF. Twenty patients with AML evolving from MDS (n = 11) or with relapsed/refractory MDS or MF (n = 9) (including 5 MDS, 2 CMML and 2 MF) were included in this group. These patients had received a median of one (range, 1-2) prior therapy. The CR/CRi rate was 35% with a median OS of 7.2 months and 8-week mortality of 15%. This was compared with a matched cohort of 23 historical controls who had previously treated MDS that progressed to AML and were treated on protocols at our center between 2001 and 2010, where the CR/CRi rate, median OS and 8-week mortality were 13% (P = 0.09), 6.5 months (P = 0.37) and 22% (P = 0.57), respectively. Decitabine in combination with GO improved the response rate compared with historical data but again did not improve the OS (Supplementary Table 1 ). Table 1 and Supplementary Figure 1 demonstrate the covariate adjusted Bayesian posterior probabilities of decitabine with GO being superior or inferior to the historical treatment for response rate and OS, respectively, within each subgroup of patient. For example, in group 1 patients, the posterior probability of decitabine+GO having a beneficial effect on response rate as compared with historical treatments is 84.6% (Supplementary  Table 1 ); and the posterior probability of decitabine+GO having a harmful effect on the OS as compared with historical treatments is only 4% (Supplementary Table 2) . Again, in group 3 patients, the posterior probability of decitabine+GO having a beneficial effect on the response rate as compared with the historical treatment is 71.5% (Supplementary Table 1) , however, for the same group of patients shows that the posterior probability of decitabine with GO having a harmful effect on OS is as high as 98% (Supplementary Table 2 ). As group 3 comprised of both untreated AML (n = 40) and untreated MDS (n = 15) and MF (n = 2) patients with different expectations of response, we analyzed the effect of therapy separately. Among patients with untreated AML (n = 40), the posterior probability of decitabine with GO having a beneficial effect on the response rate is 93.5% and that of having a harmful effect on OS is 80%. On the other hand for untreated MDS patients (n = 15), the posterior probability of decitabine with GO having a beneficial effect on the response rate is only 24% and that of having a harmful effect on OS is as high as 93%.
Statistical analysis Supplementary
Toxicity
Neutropenic fever was the most common grade 3/4 toxicity (45%) ( Table 3) . Grade 3/4 gastrointestinal and mucosal bleeding occurred in eight patients (7%). Other grade 3/4 nonhematological toxicities including nausea and mucositis were seen in five patients (5%). Cardiovascular events were observed in three patients including two cases of hypotension and one case of atrial fibrillation. Interestingly, no cases of treatment related grade 3-4 liver function abnormalities or veno-occlusive disease were identified.
Correlation of CD33 expression with response Of the 110 patients enrolled, 87 were evaluable for CD33 within 3 months before the initiation of decitabine and gemtuzumab 
DISCUSSION
Despite the voluntary withdrawal of GO from the US market, there have been several reports of survival benefit from the addition of GO to induction therapy in AML. [13] [14] [15] [16] 33 In younger patients the benefit seems to be more clearly accentuated among patients with intermediate and/or favorable risk cytogenetics. 13, 16 In older patients, the addition of GO to cytotoxic induction regimens improved the relapse risk, event-free survival and OS without improving the response rate or early mortality rate. 14, 15 The fractionated schedules of GO in these recent studies may have allowed safe delivery of cumulative smaller doses resulting in increased efficacy when compared with the previously approved dose of 9 mg/m 2 . 11, 17, 34, 35 At the time we initiated this study there existed limited data regarding the use of GO in combination with lower-intensity therapy such as hypomethylating agents and lowdose cytarabine.
On the basis of the statistical endpoints, decitabine in combination with GO improved response rate among patients with untreated AML ⩾ 60 years of age who were unfit for chemotherapy, AML evolving from treated MDS and previously treated MDS or MF. However, this did not translate into improved survival when compared with historical data. This is similar to the recently reported MRC16 trial that showed lack of survival benefit despite improved CR rates when GO was added to low-dose cytarabine in elderly untreated AML patients. 36 An important aspect of this study is that the study design performed very well in optimally channeling accrual of patients to the arms that performed well while closing accrual to the underperforming arms. Such a design takes into consideration the patients' heterogeneity among various prognostic subgroups in the same trial and the potential treatment-subgroup interactions. It can optimize patient allocation to effective therapy while minimizing exposure to ineffective therapy. The improved response rate among patients with newly diagnosed AML, which made up the bulk of group 3, resulted in continued accrual to this group in accordance with the flexible model-based Bayesian design. Thus, 52% of the patients accrued in our trial were in group 3. Historically, cytotoxic induction chemotherapy in elderly patients with AML and considered fit for such therapy produces a CR rate of 30-50% and an induction mortality of 25-40%. 3, 6, 37, 38 The 40 treatment-naive AML patients treated with decitabine and GO in our study had an overall response rate of 45% with acceptable toxicity and lower induction mortality. These outcomes compare well with those achieved with single-agent hypomethylating agents (azacytidine or decitabine) or their combinations with histone deacetylase inhibitors, for example, valproic acid or vorinostat, in comparable patients treated at our institute.
Our results with hypomethylating agent in combination with GO among treatment-naive elderly AML patients are similar to those recently reported by Nand et al. 26 The scientific premise of their study was the synergy between azacytidine and GO wherein azacytidine induced increased CD33 expression and decreased P-glycoprotein expression. [37] [38] [39] Azacytidine-or decitabinemediated chromatin relaxation is also expected to enhance binding of calicheamicin to DNA. 25 Nand et al. reported a remission rate of 44% and a median survival of 11 months in 'good-risk' treatment-naive elderly AML patients (good risk = age 60-88 and PS 0-1, median age = 72). Patients who did not have 'good-risk' features (age 70-88 and PS 2-3, median age = 75) had a remission rate and median OS of 35% and 11 months, respectively. Our study allowed PS of up to 3 and the median age in treatment-naive AML patients was 72 years.
In contrast, the untreated MDS patients had an inferior response rate with the combination as compared with a historical cohort of 103 high-risk MDS patients treated with hypomethylating agentbased therapies at our institution. Two factors may have contributed to inferior outcomes in the MDS patients treated with decitabine and GO. In the frontline decitabine trial conducted at our institution, the median age of patients was 5 years younger than our current cohort. 40 Also for various reasons including intercurrent infections the high-risk MDS patients on the decitabine and GO cohort received a median of only 3 (range, 1-13) courses of therapy as compared with a median of 7 (range, 1-49) courses of hypomethylator-based therapy in the historical cohort. Several phase III studies implementing hypomethylatorbased therapy have identified a median time to best response of 3-6 months with these agents. 41, 42 Thus, it is quite possible that the patients in our current study received a less than optimal duration of therapy resulting in inferior response rates. Irrespective of these caveats, the combination of decitabine with GO is possibly an inferior option for patients with untreated MDS.
Similar to elderly patients unfit for standard induction, patients with AML refractory to induction chemotherapy or with short remission have dismal outcomes with salvage chemotherapy. 43 The response rates become progressively worse in patients failing multiple salvages. The 28 patients with relapsed/refractory AML and a CRD o1 year (median of 1.5 months) treated on our trial had received a median of two prior salvage regimens (range, 1-5). CR/complete remission with incomplete recovery of platelets was achieved in 18% of these patients with a median OS of 4 months. These results are similar to a matched cohort of 440 patients treated on salvage studies at our institution. Of note, the combination of GO with '3+7' as first salvage in a small group of younger patients with AML has shown promising results. 44 These results need to be confirmed in larger studies in this patient population.
In summary, decitabine in combination with GO may be a suitable regimen in newly diagnosed AML patients who are not candidates for intensive induction therapy. However, the regimen produced inferior outcomes in the small cohort of treatment-naive high-risk MDS patients evaluated. In patients with relapsed/ refractory AML decitabine and GO may be a viable alternative to more intensive chemotherapy-based salvage regimens.
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